Concord Biotech Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Concord Biotech Ltd filed with BSE on 07 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Concord Biotech reported Q1 FY27 revenue of INR257 crores, up 26.2% year-on-year, driven by export growth of 46% and broad-based gains across immunosuppressants, anti-infectives, oncology and antifungal categories. EBITDA grew 34% to INR82 crores with margins of 32%, while PAT rose 31% to INR58 crores. Management attributed the growth to new product launches, wallet share gains from pricing advantages, and spillover of delayed customer procurement from the prior year.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue: INR257 crores (Q1 FY27)
p. 3
“We are pleased to report a strong start to FY27 with Q1 FY27 revenues of INR257 crores, reflecting a healthy 26% year-on-year growth.”
Ankur Vaid, page 3 of the filed PDF · View the filing
Revenue growth: 26.2% (Q1 FY27 vs Q1 FY26)
p. 5
“Revenue for Q1 FY27 stood at INR257 crores compared to INR204 crores in the Q1 FY26, a growth of 26.2%.”
Raviraj Karia, page 5 of the filed PDF · View the filing
API segment revenue: INR219 crores (Q1 FY27)
p. 5
“Revenue from API segment stood at INR219 crores, a growth of 42%.”
Raviraj Karia, page 5 of the filed PDF · View the filing
Formulation revenue: INR39 crores (Q1 FY27)
p. 5
“Formulation revenue stood at INR39 crores with a de-growth of 23%.”
Raviraj Karia, page 5 of the filed PDF · View the filing
Export revenue growth: 46% (Q1 FY27)
p. 4
“Our export business remained a key growth driver with export revenues increasing 46% year-on-year in Q1 FY27.”
Ankur Vaid, page 4 of the filed PDF · View the filing
Domestic revenue growth: 12% (Q1 FY27)
p. 5
“domestic revenues for Q1 FY27 grew by 12% and export revenues grew by 46%.”
Raviraj Karia, page 5 of the filed PDF · View the filing
Gross margin: 78.9% (Q1 FY27)
p. 5
“Gross margins for the quarter stood at 78.9%, an increase of 100 bps Y-o-Y.”
Raviraj Karia, page 5 of the filed PDF · View the filing
EBITDA: INR82 crores (Q1 FY27)
p. 5
“EBITDA for Q1 FY27 stood at INR82 crores, a growth of 34% and EBITDA margins stood at 32%, an increase of 190 bps year-on-year.”
Raviraj Karia, page 5 of the filed PDF · View the filing
EBITDA margin excluding injectable facility and Stellon: 37% (Q1 FY27)
p. 5
“EBITDA, excluding the impact of injectable facilities and expenses related to the Stellon Biotech would have been 37% for the Q1 FY27.”
Raviraj Karia, page 5 of the filed PDF · View the filing
PAT: INR58 crores (Q1 FY27)
p. 5
“Speaking of profit after tax, the PAT for the quarter stood at INR58 crores, a growth of 31% year-on-year.”
Raviraj Karia, page 5 of the filed PDF · View the filing
PAT margin: 22.4% (Q1 FY27)
p. 5
“PAT margins for the quarter stood at 22.4%, an increase of 80 bps year-on-year.”
Raviraj Karia, page 5 of the filed PDF · View the filing
Cash and cash equivalents: more than INR442 crores (as on 30th June 2026)
p. 5
“we are a zero debt company and with cash and cash equivalent of more than INR442 crores as on 30th June, our capex for the quarter stood at around INR9.5 crores.”
Raviraj Karia, page 5 of the filed PDF · View the filing
Capex: around INR9.5 crores (Q1 FY27)
p. 5
“our capex for the quarter stood at around INR9.5 crores.”
Raviraj Karia, page 5 of the filed PDF · View the filing
Unit 1 capacity utilization: around 80% (Q1 FY27)
p. 8
“So the capacity utilization for Unit 1 was around 80%.”
Raviraj Karia, page 8 of the filed PDF · View the filing
Unit 3 capacity utilization: around 55% (Q1 FY27)
p. 8
“For Unit 3, as sir mentioned, it is around 55%.”
Raviraj Karia, page 8 of the filed PDF · View the filing
Unit 2 capacity utilization: around 25% (Q1 FY27)
p. 8
“Unit 2 was around 25%.”
Raviraj Karia, page 8 of the filed PDF · View the filing
Injectable facility capacity utilization: around 5% (Q1 FY27)
p. 12
“Yes, it is around 5%.”
Ankur Vaid, page 12 of the filed PDF · View the filing
CDMO revenue contribution: 1% to 2% (Q1 FY27)
p. 9
“Talking about the CDMO business, yes, currently, it would be at around 1% to 2%.”
Ankur Vaid, page 9 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — better than historical growth rates · FY27
stated firmly by Ankur Vaid
p. 6
“So we stand on track to achieving growth better than our historical growth rates.”
Ankur Vaid, page 6 of the filed PDF · View the filing
Revenue from existing manufacturing infrastructure — INR3,000 crores · 5 to 6 years
stated as an aspiration by Ankur Vaid
p. 7
“I would say in a matter of 5 to 6 years, we expect that we should be pretty close to achieving that number because given the CAGR growth rate that we have spoken in the past, we should be pretty close to achieving the INR3,000 crores number.”
Ankur Vaid, page 7 of the filed PDF · View the filing
Formulation business revenue — INR600 crores to INR700 crores
stated as an aspiration by Ankur Vaid
p. 6
“So we expect that around INR600 crores to INR700 crores is going to be from the formulation business.”
Ankur Vaid, page 6 of the filed PDF · View the filing
API business revenue — INR2,200 crores
stated as an aspiration by Ankur Vaid
p. 6
“And the rest of the growth is going to be the balance INR2,200 crores is from the APIs.”
Ankur Vaid, page 6 of the filed PDF · View the filing
EBITDA margin — 40% · FY28
stated conditionally by Naman Bagrecha
p. 11
“Understood. So more towards FY28 is when you move towards that 40% mark?”
Naman Bagrecha, page 11 of the filed PDF · View the filing
CDMO contribution to sales — double-digit contributor
stated as an aspiration by Ankur Vaid
p. 9
“But our intent is to kind of bring it to a double-digit contributor to the overall sales numbers and we are kind of working towards that.”
Ankur Vaid, page 9 of the filed PDF · View the filing
Injectable facility sales to emerging markets — next year
stated conditionally by Ankur Vaid
p. 11
“So we expect that by next year, sales to the emerging markets would start.”
Ankur Vaid, page 11 of the filed PDF · View the filing
Injectable facility contract manufacturing commercialization — second half of the year
stated conditionally by Ankur Vaid
p. 11
“So we expect that in second half of the year, we should see some of those opportunities being commercialized.”
Ankur Vaid, page 11 of the filed PDF · View the filing
New product launches — 2 to 3 new products annually · annually
stated firmly by Ankur Vaid
p. 4
“Our product pipeline remains robust with plans to launch 2 to 3 new products annually.”
Ankur Vaid, page 4 of the filed PDF · View the filing
API capex decision timing — 80%, 85% utilization
stated conditionally by Ankur Vaid
p. 13
“So I think once the utilization levels reach to around 80%, 85%, I think at the Unit 3, I think probably that will be a time to kind of add more capacities at Unit 3”
Ankur Vaid, page 13 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said some contribution came from spillover but most growth was from new products across all geographies, and expects growth to remain above historical rates.
Answered by Ankur Vaid
Asked by Parth: How much of the growth reflects normalization of delayed procurement versus structural gains, and will the growth trajectory sustain through FY27?
p. 6
“But yes, much of the growth for Concord in this quarter has been from the new products, which are where we've been selling the products and has been across geographies.”
Ankur Vaid, page 6 of the filed PDF · View the filing
Management said all three are exciting nascent-stage opportunities and it would be difficult to pick one.
Answered by Ankur Vaid
Asked by Sajal Kapoor: Which of CDMO, injectables and Stellon has earned the most management attention?
p. 8
“So we are pretty excited for all the 3 opportunities, and they're all in very different segments. So it will be difficult for us to kind of pick one of those.”
Ankur Vaid, page 8 of the filed PDF · View the filing
Unit 1 at 80%, Unit 3 at 55%, Unit 2 at 25%; domestic formulation decline was due to loss of Middle East supply contribution from the prior year.
Answered by Raviraj Karia
Asked by Siddharth: What is capacity utilization across units and what explains the domestic formulation weakness?
p. 8
“So the capacity utilization for Unit 1 was around 80%. For Unit 3, as sir mentioned, it is around 55%. Unit 2 was around 25%.”
Raviraj Karia, page 8 of the filed PDF · View the filing
Management said it was primarily driven by competitive pricing enabled by scale economies.
Answered by Ankur Vaid
Asked by Alok Dalal: What drove higher wallet share gains this quarter?
p. 10
“So it was primarily driven by pricing.”
Ankur Vaid, page 10 of the filed PDF · View the filing
Management said the injectable facility and Stellon need to fully ramp up, and the 40% mark is more likely in FY28.
Answered by Ankur Vaid
Asked by Alok Dalal: Should EBITDA margin reach 40% by end of this fiscal year?
p. 10
“But in order to reach to the 40%, we need to have the injectable facility and Stellon business fully ramping up, which we expect that a partial amount of that would happen.”
Ankur Vaid, page 10 of the filed PDF · View the filing
Management said exhibit batches are on stability, filings are underway, and emerging market approvals typically take 12-15 months.
Answered by Ankur Vaid
Asked by Naman Bagrecha: When will the injectable plant commercialize supplies to export markets?
p. 11
“So getting the approvals in the emerging markets is a 12 to 15-month process.”
Ankur Vaid, page 11 of the filed PDF · View the filing
Management said no customer concerns have been raised on this.
Answered by Ankur Vaid
Asked by Naman Bagrecha: Is there any concern about newly announced US tariffs on generics impacting API sales?
p. 13
“We have not heard anything from our customers on any of the concerns on this.”
Ankur Vaid, page 13 of the filed PDF · View the filing
Management explained that oncology products generate disproportionately higher revenue per unit of capacity, and pipeline products across anti-infectives and antifungals will fill Unit 3 capacity.
Answered by Ankur Vaid
Asked by Ritika Agarwal: How will API revenue more than double to INR2,200 crores without adding capacity given current utilization levels?
p. 15
“So at times, capacity utilization also is not a true reflection of what the revenue could get generated from that because certain oncology products could generate larger value revenue compared to other products.”
Ankur Vaid, page 15 of the filed PDF · View the filing
Risks flagged
FY26 headwinds from shifts in customer buying patterns, CDSCO approval delays and tariff-related uncertainties
p. 3
“We encountered multiple headwinds, including shifts in customer buying patterns, delays in obtaining CDSCO approval and tariff-related uncertainties that impacted customer procurement decisions for both current and future supplies.”
Ankur Vaid, page 3 of the filed PDF · View the filing
Delays in injectable facility ramp-up due to inspections, approvals and facility qualification
p. 14
“Those delays that happened were primarily on account of getting the inspections and the approvals, which is again a time-consuming process.”
Ankur Vaid, page 14 of the filed PDF · View the filing
Loss of Middle East supply contribution impacting domestic formulation sales
p. 9
“So there was a contribution which was built in, in the domestic sales, which was not the case in this specific quarter.”
Ankur Vaid, page 9 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.